Literature DB >> 25526712

Bone health management in men undergoing ADT: examining enablers and barriers to care.

A N Damji1, K Bies, S M H Alibhai, J M Jones.   

Abstract

UNLABELLED: The study determined prostate cancer specialists' knowledge and concordance to guidelines regarding the diagnosis, management, and prevention of androgen deprivation therapy-induced osteoporosis. Despite high knowledge regarding bone health, most respondents did not routinely measure bone mineral density or use fracture risk assessment tools, suggesting a significant gap in the screening/monitoring of bone health.
INTRODUCTION: The purpose of this study was to determine prostate cancer specialists' knowledge, practices, self-perceived competencies and barriers to providing guideline-concordant care in the diagnosis, prevention, and management of androgen deprivation therapy (ADT)-induced osteoporosis (OP).
METHODS: A number of 73 Canadian radiation oncologists and 83 urologists completed questionnaires assessing (i) knowledge regarding OP and consensus guidelines for bone health management in men receiving ADT, (ii) self-assessed competencies regarding bone health management, (iii) current practices regarding OP prevention and management, and (iv) self-perceived barriers to providing guideline-concordant care.
RESULTS: The majority of respondents were able to correctly identify the guideline-concordant frequency of repeat dual-energy X-Ray absorptiometry (DXA) scans (76.3%), vitamin D (70.3%), and calcium (53.2%) intake and that bisphosphonates/denosumab should always be considered for patients with a history of one low-trauma fracture (57.6%). Just under 1/3 (32.5%) reported routinely measuring bone mineral density (BMD) prior to starting ADT and routinely measuring BMD 1-2 years following the initiation of ADT (36.6%). Only 4.6% of respondents routinely used a validated fracture risk assessment tool. Lowest self-assessed competency levels were reported in providing self-management education to patients to foster the uptake of healthy bone behaviors (HBBs) and managing patients who present with or develop osteopenia and OP. The most significant barriers to providing OP prevention and management were lack of time and lack of supporting structures.
CONCLUSIONS: Despite high knowledge about appropriate bone health care among prostate cancer specialists, there remain significant gaps in screening and monitoring of bone health, suggesting the need to develop innovative strategies to overcome barriers to implementation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25526712     DOI: 10.1007/s00198-014-2997-6

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  39 in total

1.  2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary.

Authors:  Alexandra Papaioannou; Suzanne Morin; Angela M Cheung; Stephanie Atkinson; Jacques P Brown; Sidney Feldman; David A Hanley; Anthony Hodsman; Sophie A Jamal; Stephanie M Kaiser; Brent Kvern; Kerry Siminoski; William D Leslie
Journal:  CMAJ       Date:  2010-10-12       Impact factor: 8.262

2.  Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer.

Authors:  Kouta Ito; Elena B Elkin; Monica Girotra; Michael J Morris
Journal:  Ann Intern Med       Date:  2010-05-18       Impact factor: 25.391

3.  Implementation of osteoporosis screening guidelines in prostate cancer patients on androgen ablation.

Authors:  Lindsay S Van Tongeren; Graeme G Duncan; David L Kendler; Howard Pai
Journal:  J Clin Densitom       Date:  2009-07-09       Impact factor: 2.617

4.  Evaluation of osteoporosis risk assessment in veterans receiving androgen-deprivation therapy.

Authors:  Valerie D'Alesio; Brent E Salvig; T Neal Fourakre
Journal:  Consult Pharm       Date:  2011-01

5.  Bone density testing among prostate cancer survivors treated with androgen-deprivation therapy.

Authors:  Alicia K Morgans; Matthew R Smith; A James O'Malley; Nancy L Keating
Journal:  Cancer       Date:  2012-10-12       Impact factor: 6.860

6.  Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications.

Authors:  Yu-Hsuan Shao; Dirk F Moore; Weichung Shih; Yong Lin; Thomas L Jang; Grace L Lu-Yao
Journal:  BJU Int       Date:  2013-01-17       Impact factor: 5.588

7.  Electronic medical record reminder improves osteoporosis management after a fracture: a randomized, controlled trial.

Authors:  Adrianne Feldstein; Patricia J Elmer; David H Smith; Michael Herson; Eric Orwoll; Chuhe Chen; Mikel Aickin; Martha C Swain
Journal:  J Am Geriatr Soc       Date:  2006-03       Impact factor: 5.562

8.  Management of decreased bone mineral density in men starting androgen-deprivation therapy for prostate cancer.

Authors:  Abbas H Panju; Henriette Breunis; Angela M Cheung; Marc Leach; Neil Fleshner; Padraig Warde; Sarah Duff-Canning; Murray Krahn; Gary Naglie; Ian Tannock; George Tomlinson; Shabbir M H Alibhai
Journal:  BJU Int       Date:  2008-10-24       Impact factor: 5.588

Review 9.  Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies.

Authors:  Terrence H Diamond; Celestia S Higano; Matthew R Smith; Theresa A Guise; Frederick R Singer
Journal:  Cancer       Date:  2004-03-01       Impact factor: 6.860

Review 10.  Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis.

Authors:  Mark J Bolland; Alison Avenell; John A Baron; Andrew Grey; Graeme S MacLennan; Greg D Gamble; Ian R Reid
Journal:  BMJ       Date:  2010-07-29
View more
  11 in total

Review 1.  Adverse bone effects of medications used to treat non-skeletal disorders.

Authors:  N B Watts
Journal:  Osteoporos Int       Date:  2017-07-27       Impact factor: 4.507

2.  Canadian Urological Association best practice report: Bone health in prostate cancer.

Authors:  Luke T Lavallée; Ryan McLarty; Christopher Tran; Rodney H Breau; Patrick Richard; Bobby Shayegan; Brita Danielson; Marie-Paul Jammal; Fred Saad
Journal:  Can Urol Assoc J       Date:  2021-12       Impact factor: 1.862

3.  Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert group.

Authors:  Janet E Brown; Catherine Handforth; Juliet E Compston; William Cross; Nigel Parr; Peter Selby; Steven Wood; Lawrence Drudge-Coates; Jennifer S Walsh; Caroline Mitchell; Fiona J Collinson; Robert E Coleman; Nicholas James; Roger Francis; David M Reid; Eugene McCloskey
Journal:  J Bone Oncol       Date:  2020-08-02       Impact factor: 4.072

4.  Comparison of fracture risk assessment tools in older men without prior hip or spine fracture: the MrOS study.

Authors:  Margaret L Gourlay; Victor S Ritter; Jason P Fine; Robert A Overman; John T Schousboe; Peggy M Cawthon; Eric S Orwoll; Tuan V Nguyen; Nancy E Lane; Steven R Cummings; Deborah M Kado; Jodi A Lapidus; Susan J Diem; Kristine E Ensrud
Journal:  Arch Osteoporos       Date:  2017-10-20       Impact factor: 2.617

Review 5.  Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures.

Authors:  N C W Harvey; E V McCloskey; P J Mitchell; B Dawson-Hughes; D D Pierroz; J-Y Reginster; R Rizzoli; C Cooper; J A Kanis
Journal:  Osteoporos Int       Date:  2017-02-07       Impact factor: 4.507

Review 6.  The prevention of fragility fractures in patients with non-metastatic prostate cancer: a position statement by the international osteoporosis foundation.

Authors:  Luisella Cianferotti; Francesco Bertoldo; Marco Carini; John A Kanis; Alberto Lapini; Nicola Longo; Giuseppe Martorana; Vincenzo Mirone; Jean-Yves Reginster; Rene Rizzoli; Maria Luisa Brandi
Journal:  Oncotarget       Date:  2017-05-18

7.  Harnessing the potential of therapeutic agents to safeguard bone health in prostate cancer.

Authors:  Kurt Miller; Günther G Steger; Daniela Niepel; Diana Lüftner
Journal:  Prostate Cancer Prostatic Dis       Date:  2018-07-09       Impact factor: 5.554

Review 8.  Bone Health in Men with Prostate Cancer: Review Article.

Authors:  Salma A M El Badri; Abdulazeez Salawu; Janet E Brown
Journal:  Curr Osteoporos Rep       Date:  2019-12       Impact factor: 5.096

9.  Attention to bone health in follow-up of gynaecological cancers in tertiary care.

Authors:  Catherine A O'Gorman; Sorcha Minnock; Joseph Mulhall; Noreen Gleeson
Journal:  Womens Health (Lond)       Date:  2022 Jan-Dec

Review 10.  Pathophysiology of Bone Loss in Patients with Prostate Cancer Receiving Androgen-Deprivation Therapy and Lifestyle Modifications for the Management of Bone Health: A Comprehensive Review.

Authors:  Tae Jin Kim; Kyo Chul Koo
Journal:  Cancers (Basel)       Date:  2020-06-10       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.